解码Cdc25A在肿瘤能量代谢中的作用

Cdc25A是在细胞周期中起关键作用的蛋白磷酸酶，它在多种肿瘤中高表达。然而，Cdc25A在肿瘤能量代谢中的作用还不清楚。我们的研究表明，EGF可诱导胞浆中丙酮酸激酶M2（PKM2）磷酸化，促使PKM2进入细胞核。在细胞核中，PKM2与Cdc25A结合并被其去磷酸化，这一过程对于EGF诱导的β-catenin活化是必须的。因此，我们提出假说，Cdc25A通过去磷酸细胞核中的PKM2从而调节肿瘤能量代谢和肿瘤进展。要验证这一假说，我们提出以下目标：（1）进一步阐释Cdc25A依赖的PKM2去磷酸化以及β-catenin激活的分子机制；（2）明确Cdc25A依赖的PKM2去磷酸化在Warburg效应、肿瘤细胞生长和胶质瘤形成中的作用；（3）明确Cdc25A依赖的PKM2去磷酸化在胶质瘤中的临床意义。这项研究有助于开发药物，通过阻断Cdc25A的功能抑制肿瘤能量代谢，最终提高肿瘤临床治疗效果。

Cdc25A is an instrumental protein phosphatase in cell cycle progression that is overexpressed in many types of human cancer. However, the role of Cdc25A in cancer metabolism is unclear, and although its role in the regulation of Cdk dephosphorylation is well established, Cdc25A may contain other important cellular substrates. We revealed that EGF stimulation induces PKM2 phosphorylation in the cytosol, which is essential for the nuclear translocation of PKM2. In the nucleus, PKM2 is dephosphorylated by interacting with Cdc25A, which is required for EGF-induced β-catenin transactivation. We hypothesize that Cdc25A regulates cancer metabolism and tumor progression by dephosphorylating nuclear PKM2. To test this hypothesis, we will pursue three specific aims: (1) To further elucidate the mechanisms underlying Cdc25A-dependent PKM2 dephosphorylation and the subsequent activation of β-catenin; (2) To determine the role of Cdc25A-dependent PKM2 dephosphorylation in the Warburg effect, tumor cell proliferation, and brain tumorigenesis; and (3) To determine the clinical significance of Cdc25A-dependent PKM2 dephosphorylation in human glioma. The proposed research is significant because it could lead to pharmaceutical approaches to interrupt cancer metabolism by blocking the function of Cdc25A; this would, in turn, improve the efficacy of human cancer treatment.